Tafinlar and Electrocardiogram qt prolonged - a phase IV clinical study of FDA data

Summary:

Electrocardiogram qt prolonged is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Mekinist, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Electrocardiogram qt prolonged when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Electrocardiogram qt prolonged?

Electrocardiogram qt prolonged is found to be associated with 1,394 drugs and 1,518 conditions by eHealthMe. Check the latest studies of Electrocardiogram qt prolonged.

On Jul, 13, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 74 people (0.45%) have Electrocardiogram qt prolonged.

Could Tafinlar cause Electrocardiogram qt prolonged?

Among these 74 people:

How long have people been on Tafinlar when they have Electrocardiogram qt prolonged? *

What is the gender of people who have Electrocardiogram qt prolonged when taking Tafinlar? *

female: 51.47 %
male: 48.53 %

What is the age of people who have Electrocardiogram qt prolonged when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

What are other side effects people have besides Electrocardiogram qt prolonged? *

Fever: 27 people, 36.49%
Malignant Neoplasm Progression (cancer tumour came back): 18 people, 24.32%
Fatigue (feeling of tiredness): 15 people, 20.27%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 13 people, 17.57%
Chills (felling of cold): 12 people, 16.22%
Blood Creatine Phosphokinase Increased: 12 people, 16.22%
Malignant Melanoma (skin cancer rises from melancytes): 10 people, 13.51%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 10 people, 13.51%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 10 people, 13.51%
Nausea (feeling of having an urge to vomit): 10 people, 13.51%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 36 people, 48.65%
Malignant Melanoma (skin cancer rises from melancytes): 25 people, 33.78%
High Blood Pressure: 12 people, 16.22%
Lung Cancer - Non-Small Cell (lung cancer): 10 people, 13.51%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 7 people, 9.46%
Metastases To Central Nervous System (cancer spreads to central nervous system): 6 people, 8.11%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 5 people, 6.76%
Malignant Melanoma Stage Iii (cancer has spread to one or more lymph nodes): 5 people, 6.76%
Diabetes: 4 people, 5.41%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 4.05%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Electrocardiogram qt prolonged?

- Check whether Electrocardiogram qt prolonged is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Electrocardiogram qt prolonged:

Electrocardiogram qt prolonged (1,394 drugs)

Browse all the conditions that are associated with Electrocardiogram qt prolonged:

Electrocardiogram qt prolonged (1,518 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.